Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CVMNASDAQ:FRTXNASDAQ:OMGANASDAQ:PTE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCEL-SCI$2.29-1.3%$5.41$1.98▼$66.60$6.94M0.2773,325 shs2.09 million shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsOMGAOmega Therapeutics$0.13-21.8%$0.12$0.10▼$2.63$6.92M1.653.38 million shs4.81 million shsPTEPolarityTE$0.37$0.20▼$1.90$1.78M1.15249,591 shs8.50 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCEL-SCI0.00%-3.38%-55.19%-70.64%-93.12%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%-0.04%OMGAOmega Therapeutics0.00%0.00%0.00%0.00%-94.37%PTEPolarityTE0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVMCEL-SCI0.0971 of 5 stars0.02.00.00.00.60.00.6FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOMGAOmega Therapeutics2.2109 of 5 stars3.40.00.00.01.11.71.3PTEPolarityTEN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCEL-SCI 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AOMGAOmega Therapeutics 2.80Moderate Buy$8.506,700.00% UpsidePTEPolarityTE 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56OMGAOmega Therapeutics$8.10M0.85N/AN/A$1.05 per share0.12PTEPolarityTE$810K0.00N/AN/A$2.30 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AOMGAOmega Therapeutics-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%6/20/2025 (Estimated)PTEPolarityTE-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCEL-SCIN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AOMGAOmega TherapeuticsN/AN/AN/AN/AN/APTEPolarityTEN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCEL-SCI0.661.071.09FRTXFresh Tracks TherapeuticsN/AN/AN/AOMGAOmega Therapeutics1.001.611.61PTEPolarityTEN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCEL-SCI12.08%FRTXFresh Tracks Therapeutics25.04%OMGAOmega Therapeutics97.47%PTEPolarityTE11.75%Insider OwnershipCompanyInsider OwnershipCVMCEL-SCI9.93%FRTXFresh Tracks Therapeutics0.23%OMGAOmega Therapeutics8.50%PTEPolarityTE5.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCEL-SCI433.03 million64.67 millionOptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableOMGAOmega Therapeutics12055.37 million50.66 millionOptionablePTEPolarityTE427.38 million6.98 millionOptionablePTE, OMGA, CVM, and FRTX HeadlinesRecent News About These CompaniesPioneering Technology Reports 2025 Q2 Financial ResultsMay 30, 2025 | thenewswire.comMomentum Builds for ScanTech AI Systems at PTE Madrid 2025 as Industry Embraces AI-Powered SecurityApril 9, 2025 | globenewswire.comRegenetp Inc RGTPQApril 19, 2024 | morningstar.comNEW INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PolarityTE, Inc. & Encourages Inves...January 10, 2024 | br.advfn.comRegenETP, Inc. (NJT.SG)January 6, 2024 | finance.yahoo.comPolarityTE Inc. [PTE] Investment Appeal on the RiseJune 14, 2023 | knoxdaily.comPolarityTE Stock (NASDAQ:PTE), DividendsJune 9, 2023 | benzinga.comPolarityTE shares are trading lower after the company filed voluntary petitions for relief under Chapter 11.June 7, 2023 | benzinga.comPolarityTE, Inc. (PTE) stock price, news, quote & history – Yahoo FinanceMay 15, 2023 | uk.finance.yahoo.comSkin Replacement Market Recent Technological Advancements to ... - Digital JournalMay 4, 2023 | news.google.comDismissal of Securities Claims Against Utah Biotech Company ... - JD SupraApril 30, 2023 | news.google.comPolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You ... - NasdaqApril 25, 2023 | news.google.comPolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 25, 2023 | finance.yahoo.comPolarityTE Avoids Lawsuit Over Skin Graft Product Disclosures - Bloomberg LawApril 20, 2023 | news.google.comChronic Wound Care Market is expected to reach a valuation of US ... - Digital JournalApril 12, 2023 | news.google.comForm DEF 14A ENERGY FUELS INC - StreetInsider.comApril 5, 2023 | news.google.comPolarityTE Full Year 2022 Earnings: EPS Misses Expectations - Yahoo FinanceMarch 29, 2023 | news.google.comPolarityTE Full Year 2022 Earnings: EPS Misses ExpectationsMarch 29, 2023 | finance.yahoo.comBiodexa Pharmaceuticals Stock (NASDAQ:BDRX), Quotes and ... - BenzingaMarch 28, 2023 | news.google.comStocks That Hit 52-Week Lows On Tuesday - Sono Group (NASDAQ ... - BenzingaMarch 28, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyPTE, OMGA, CVM, and FRTX Company DescriptionsCEL-SCI NYSE:CVM$2.29 -0.03 (-1.29%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.30 +0.01 (+0.48%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Omega Therapeutics NASDAQ:OMGA$0.12 -0.03 (-21.83%) Closing price 02/24/2025Extended Trading$0.12 0.00 (0.00%) As of 02/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.PolarityTE NASDAQ:PTEPolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
